The European Medicines Agency has recommended the authorization of two new medicines against the coronavirus for people at risk of severe disease.
In a statement on Thursday, the EU drug regulator said it had concluded that the monoclonal antibody treatments -- a combination of casirivimab and imdevimab, and the drug regdanvimab -- have both been proven to significantly reduce the risk of hospitalization and death in patients vulnerable to serious COVID-19.
Read more at:
EU authorizes 2 medicines for people at risk of severe COVID-19 | CTV News
